DSM Capital Partners LLC Acquires 49,175 Shares of Novo Nordisk A/S (NYSE:NVO)

DSM Capital Partners LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 2.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,056,587 shares of the company's stock after acquiring an additional 49,175 shares during the quarter. Novo Nordisk A/S accounts for about 2.5% of DSM Capital Partners LLC's investment portfolio, making the stock its 12th biggest position. DSM Capital Partners LLC's holdings in Novo Nordisk A/S were worth $142,809,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in NVO. Strategic Investment Solutions Inc. IL increased its stake in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the period. Copeland Capital Management LLC increased its stake in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the period. North Capital Inc. bought a new stake in Novo Nordisk A/S during the first quarter worth about $27,000. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth about $29,000. Finally, Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S during the first quarter worth about $30,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 2.2%

Shares of NYSE NVO opened at $50.90 on Thursday. The company's 50 day simple moving average is $65.84 and its 200 day simple moving average is $70.91. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $139.74. The firm has a market capitalization of $227.27 billion, a P/E ratio of 13.98, a P/E/G ratio of 1.71 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be given a dividend of $0.4119 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is currently 45.05%.

Analysts Set New Price Targets

Several analysts have weighed in on NVO shares. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a research note on Thursday, July 31st. Finally, BNP Paribas Exane raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target for the company in a report on Wednesday. One analyst has rated the stock with a sell rating, twelve have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $83.75.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.